Список проголосовавших за комментарий "Биотехнолог, <table cellspacing="0" cellpadding="0"><tr> <td><span>Note 9.</span></td> <td><span>Stockholders' Equity</span></td> </tr></table><span>Share Repurchase Program</span><span>In November 2016, our board of directors authorized a </span><span>$6.0 billion</span><span> share repurchase program of our Class A common stock, which commenced in 2017 and does not have an expiration date. We completed repurchases under this authorization during the second quarter of 2018. In April 2018, the authorization of the repurchase of our Class A common stock was increased by an additional </span><span>$9.0 billion</span><span>. During the </span><span>nine</span><span> months ended </span><span>September 30, 2018</span><span>, we repurchased and subsequently retired approximately </span><span>54 million</span><span> shares of our Class A common stock for an aggregate amount of approximately </span><span>$9.39 billion</span><span>. As of </span><span>September 30, 2018</span><span>, approximately </span><span>$3.54 billion</span><span> remained available and authorized for repurchases. The timing and actual number of shares repurchased under this program depend on a variety of factors, including price, general business and market conditions, and other investment opportunities, and shares may be repurchased through open market purchases or privately negotiated transactions, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.</span><span> </span>"